Last reviewed · How we verify

Hydrocortisone 2.5% — Competitive Intelligence Brief

Hydrocortisone 2.5% (Hydrocortisone 2.5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glucocorticoid. Area: Dermatology.

marketed Glucocorticoid Glucocorticoid receptor (GR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Hydrocortisone 2.5% (Hydrocortisone 2.5%) — University of the Pacific. Hydrocortisone is a glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hydrocortisone 2.5% TARGET Hydrocortisone 2.5% University of the Pacific marketed Glucocorticoid Glucocorticoid receptor (GR)
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) marketed Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Prelone prednisolone Generic (originally Schering) marketed Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Modified release hydrocortisone Modified release hydrocortisone The Adelaide and Meath Hospital, incorporating The National Children's Hospital marketed Glucocorticoid Glucocorticoid receptor
phosphate and betamethasone acetate, 2 mL. phosphate and betamethasone acetate, 2 mL. Hospital Italiano de Buenos Aires marketed Corticosteroid (glucocorticoid) Glucocorticoid receptor (GR)
Corticosteroids (Prednisone) Corticosteroids (Prednisone) Astellas Pharma Inc marketed Corticosteroid (glucocorticoid) Glucocorticoid receptor (GR)
Oral Corticosteroid (OCS) Oral Corticosteroid (OCS) Teva Branded Pharmaceutical Products R&D, Inc. marketed Glucocorticoid Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glucocorticoid class)

  1. Research in Real-Life Ltd · 2 drugs in this class
  2. NICHD Neonatal Research Network · 2 drugs in this class
  3. UMC Utrecht · 2 drugs in this class
  4. University of Pennsylvania · 2 drugs in this class
  5. First Affiliated Hospital of Zhejiang University · 1 drug in this class
  6. GlaxoSmithKline · 1 drug in this class
  7. ClinAmygate · 1 drug in this class
  8. Instituto de Investigación Sanitaria y Biomédica de Alicante · 1 drug in this class
  9. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  10. Guangzhou JOYO Pharma Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydrocortisone 2.5% — Competitive Intelligence Brief. https://druglandscape.com/ci/hydrocortisone-2-5. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: